Biologic Biosimilar Savings: How Much You'll Cut Off Humira, Remicade, and Stelara

The $83,000 quote for a year of Humira is normal — and here’s the part that should make you exhale: biosimilars can knock 30-50% off that list price. Whether that discount reaches your wallet or just your insurer’s depends on details most patients never get explained. Let’s fix that.

Biosimilars are FDA-approved versions of biologic drugs that come to market after the original loses patent protection. The first U.S. biosimilar launched in 2015, and by 2023 nearly a dozen adalimumab biosimilars had arrived to compete with Humira. They’re not generics — biologics are too complex to copy exactly — but the FDA holds them to a strict clinical-equivalence standard.

Biosimilar Savings by Drug

Notice that the newest drugs — Skyrizi and Rinvoq — still have no biosimilars, so their list prices have no downward pressure. The older anti-TNF agents are where the biggest discounts live.

Where the Savings Actually Go

This is the part that confuses everyone. A biosimilar’s discount lowers the net price, but who benefits depends on your situation:

• If you have a $0 copay card for the brand, switching to a biosimilar may not change your personal out-of-pocket at all. The savings flow to your insurer.
• If you’re uninsured or paying coinsurance, the lower price can mean thousands in direct savings.
• If you’re on a self-funded employer plan, the company saves, which can keep your premiums down indirectly.

Interchangeable vs. Non-Interchangeable

The FDA designates some biosimilars as “interchangeable,” meaning a pharmacist can substitute them for the brand without a new prescription, much like a generic. Others require your doctor to actively prescribe them. Both are equally safe and effective by FDA standard — the interchangeable label is about pharmacy substitution rules, not quality.

One thing worth understanding: biosimilars don’t always launch cheap. When the first adalimumab biosimilars arrived in 2023, several priced close to brand Humira at first, then dropped as more competitors entered. Prices generally fall over time as the market gets crowded, so a biosimilar that wasn’t worth switching to last year may be a clear win now. It pays to re-check pricing each plan year rather than assuming the math hasn’t changed.

Biosimilars in IBD Treatment

Most biosimilar savings in gastroenterology apply to the IBD biologics. For the full drug-by-drug picture, see our Crohn’s disease biologic medication cost guide and the ulcerative colitis medication cost breakdown. Before any biologic, insurers usually require cheaper drugs first — covered in our mesalamine medication cost guide.

If your disease can’t be controlled by medication, the conversation may shift to surgery. Our Crohn’s disease surgery cost guide covers that very different financial picture.

What to Ask Before Switching

When your insurer or pharmacy proposes a biosimilar switch:

• Ask whether your current copay card still applies, and if not, whether the biosimilar has its own assistance program.
• Confirm your GI doctor is comfortable with the specific biosimilar.
• Compare your out-of-pocket on both, in writing, before agreeing.

The Bottom Line

Biosimilars are the most powerful cost lever in the biologic world, cutting list prices 30-50% on drugs like Humira and Remicade. But the savings reach different people differently — insurers, employers, or you, depending on how you pay. If you already pay $0 with a copay card, a switch may not change your bill, while uninsured and coinsurance patients can save thousands. Always run both prices under your plan before deciding, and lean on your specialty pharmacy to do the math.